Zoetis Inc. (NYSE:ZTS) Stock Rating Reaffirmed by Goldman Sachs Group, Inc. (The)
Zoetis Inc. (NYSE:ZTS)‘s stock had its “neutral” rating restated by equities research analysts at Goldman Sachs Group, Inc. (The) in a note issued to investors on Monday, Marketbeat Ratings reports. They currently have a $62.00 target price on the stock. Goldman Sachs Group, Inc. (The)’s price target indicates a potential upside of 3.33% from the company’s current price.
Other analysts have also recently issued reports about the stock. Zacks Investment Research raised shares of Zoetis from a “hold” rating to a “buy” rating and set a $67.00 price objective on the stock in a research note on Wednesday, May 10th. Jefferies Group LLC upped their price objective on shares of Zoetis from $65.00 to $70.00 and gave the stock a “buy” rating in a research note on Tuesday, May 9th. BMO Capital Markets reaffirmed a “buy” rating and set a $60.00 price objective on shares of Zoetis in a research note on Thursday, May 4th. Argus reaffirmed a “buy” rating and set a $69.00 price objective (up from $60.00) on shares of Zoetis in a research note on Tuesday, May 30th. Finally, CL King initiated coverage on shares of Zoetis in a research note on Friday, May 26th. They set a “buy” rating and a $71.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and twelve have given a buy rating to the company’s stock. Zoetis currently has a consensus rating of “Buy” and an average price target of $64.78.
Shares of Zoetis (ZTS) opened at 60.00 on Monday. The stock’s 50 day moving average price is $62.59 and its 200 day moving average price is $57.66. Zoetis has a 52 week low of $46.86 and a 52 week high of $63.85. The firm has a market capitalization of $29.45 billion, a P/E ratio of 34.88 and a beta of 1.02.
Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Tuesday, August 8th. The company reported $0.53 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.53. The firm had revenue of $1.27 billion for the quarter, compared to analysts’ expectations of $1.27 billion. Zoetis had a net margin of 17.25% and a return on equity of 65.35%. The company’s quarterly revenue was up 5.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.49 earnings per share. On average, analysts predict that Zoetis will post $2.33 EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “Zoetis Inc. (NYSE:ZTS) Stock Rating Reaffirmed by Goldman Sachs Group, Inc. (The)” was first reported by Daily Political and is owned by of Daily Political. If you are accessing this article on another domain, it was stolen and reposted in violation of international copyright & trademark law. The legal version of this article can be accessed at https://www.dailypolitical.com/2017/08/09/zoetis-inc-nysezts-stock-rating-reaffirmed-by-goldman-sachs-group-inc-the.html.
In related news, insider Catherine A. Knupp sold 5,785 shares of the stock in a transaction that occurred on Friday, May 12th. The shares were sold at an average price of $60.16, for a total value of $348,025.60. Following the transaction, the insider now directly owns 24,415 shares in the company, valued at $1,468,806.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.31% of the stock is currently owned by corporate insiders.
Institutional investors have recently made changes to their positions in the stock. BlackRock Inc. raised its position in shares of Zoetis by 2,471.1% in the first quarter. BlackRock Inc. now owns 36,082,470 shares of the company’s stock valued at $1,925,722,000 after buying an additional 34,679,064 shares in the last quarter. Morgan Stanley raised its position in shares of Zoetis by 182.5% in the first quarter. Morgan Stanley now owns 14,617,205 shares of the company’s stock valued at $780,119,000 after buying an additional 9,442,207 shares in the last quarter. Marshall Wace North America L.P. acquired a new position in shares of Zoetis during the first quarter valued at $243,854,000. Waddell & Reed Financial Inc. raised its position in shares of Zoetis by 65.9% in the first quarter. Waddell & Reed Financial Inc. now owns 5,434,371 shares of the company’s stock valued at $290,033,000 after buying an additional 2,157,803 shares in the last quarter. Finally, California Public Employees Retirement System raised its position in shares of Zoetis by 98.9% in the first quarter. California Public Employees Retirement System now owns 2,455,700 shares of the company’s stock valued at $131,258,000 after buying an additional 1,221,200 shares in the last quarter. Institutional investors and hedge funds own 94.51% of the company’s stock.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.